rofecoxib has been researched along with Hyperpotassemia in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Five days before admission, rofecoxib, a new selective COX-2 inhibitor nonsteroidal anti-inflammatory drug (NSAID), was added for leg pain." | 3.71 | Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. ( Armoni, M; Bukish, N; Derazon, H; Hay, E; Katz, L; Kruglyakov, I, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hay, E | 1 |
| Derazon, H | 1 |
| Bukish, N | 1 |
| Katz, L | 1 |
| Kruglyakov, I | 1 |
| Armoni, M | 1 |
1 other study available for rofecoxib and Hyperpotassemia
| Article | Year |
|---|---|
Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cyclooxygenase Inhibitors; Diet; Drug Interactions; | 2002 |